References

Abaza, Yasmin, Hagop Kantarjian, Guillermo Garcia-Manero, et al. 2017. “Long-Term Outcome of Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab.” Blood 129 (10): 1275–83. https://doi.org/10.1182/blood-2016-09-736686.
Braun, Thorsten, Sophie Cereja, Sylvie Chevret, et al. 2015. “Evolving Characteristics and Outcome of Secondary Acute Promyelocytic Leukemia (APL): A Prospective Analysis by the French-Belgian-Swiss APL Group.” Cancer 121 (14): 2393–99. https://doi.org/10.1002/cncr.29389.
Dutta, Deepshikha, Hasmukh Jain, Manju Sengar, Vikram Mathews, and Syed K. Hasan. 2023. “AML-282 Venetoclax Upregulates Mitochondrial Stress Response to Overcome the Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia.” Clinical Lymphoma Myeloma and Leukemia 23 (September): S285. https://doi.org/10.1016/s2152-2650(23)01029-7.
Epstein-Peterson, Zachary D., Andriy Derkach, Susan Geyer, et al. 2022. “Effect of Additional Cytogenetic Abnormalities on Survival in Arsenic Trioxide-Treated Acute Promyelocytic Leukemia.” Blood Advances 6 (11): 3433–39. https://doi.org/10.1182/bloodadvances.2021006682.
Gill, Harinder, Yammy Yung, Hiu-Tung Chu, et al. 2021. “Characteristics and Predictors of Early Hospital Deaths in Newly Diagnosed APL: A 13-Year Population-Wide Study.” Blood Advances 5 (14): 2829–38. https://doi.org/10.1182/bloodadvances.2021004789.
Hu, Jiong, Yuan-Fang Liu, Chuan-Feng Wu, et al. 2009. “Long-Term Efficacy and Safety of All-Trans Retinoic Acid/Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.” Proceedings of the National Academy of Sciences 106 (9): 3342–47. https://doi.org/10.1073/pnas.0813280106.
Jen, Wei-Ying, Jennifer Marvin-Peek, Hagop M. Kantarjian, et al. 2024. “Long-Term Follow-up of a Phase 2 Study of All-Trans Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Acute Promyelocytic Leukemia.” Cancer 131 (1). https://doi.org/10.1002/cncr.35662.
Jiang, Bingqian, Hongyan Tong, Haitao Meng, et al. 2025. “Characteristics and Predictors of Central Nervous System Relapse in Newly Diagnosed Acute Promyelocytic Leukemia in the Era of Arsenic: A 13-Year Monocenter Cohort Study.” Blood Cancer Journal 15 (1). https://doi.org/10.1038/s41408-025-01247-3.
Knuth, Donald E. 1984. “Literate Programming.” Comput. J. (USA) 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.
Lancet, Jeffrey E., Anna B. Moseley, Steven E. Coutre, et al. 2020. “A Phase 2 Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with High-Risk APL (SWOG 0535).” Blood Advances 4 (8): 1683–89. https://doi.org/10.1182/bloodadvances.2019001278.
Shen, Zhi-Xiang, Zhan-Zhong Shi, Jing Fang, et al. 2004. “All-Trans Retinoic Acid/as 2 o 3 Combination Yields a High Quality Remission and Survival in Newly Diagnosed Acute Promyelocytic Leukemia.” Proceedings of the National Academy of Sciences 101 (15): 5328–35. https://doi.org/10.1073/pnas.0400053101.
Tashiro, Haruko, Ryosuke Shirasaki, Yoko Oka, et al. 2011. “FLT3 Internal Tandem Duplication Is Associated with a High Relapse Rate and Central Nervous System Involvement in Acute Promyelocytic Leukemia Cases: Single Institutional Analysis.” European Journal of Haematology 86 (3): 272–73. https://doi.org/10.1111/j.1600-0609.2010.01559.x.
Wang, Qian Qian, Hua-Feng Wang, Jian-Zhi Zhao, Hua Naranmandura, Jie Jin, and Hong-Hu Zhu. 2022. “Venetoclax for Arsenic-Resistant Acute Promyelocytic Leukaemia.” British Journal of Haematology 197 (5). https://doi.org/10.1111/bjh.18061.